Company intelligence / Profile preview

Imara Therapeutics

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Imara's lead drug candidate tovinontrine (IMR-687) is an oral, highly selective small-molecule inhibitor of PDE9 being developed to reduce red blood cell sickling and vascular occlusion in sickle cell disease patients; clinical results and updates indicate ongoing Phase 2 trial activity, but no late-stage or pivotal data reported in cited sources

Therapeutic areas: HematologyRare Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Cydan Development

Beyond the preview

Go deeper on Imara Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imara Therapeutics.

Explore the full profile